Results 131 to 140 of about 14,172 (227)

Identification and characterization of mutations that confer resistance to ethambutol and pyrazinamide in Mycobacterium tuberculosis [PDF]

Background: The global rate of antimicrobial resistance is rising for M. tuberculosis, the leading causative agent of tuberculosis infections. Gold standard phenotypic methods for drug susceptibility testing (DST) are slow and labor-intensive, but rapid ...
Hiebert, Morgan
core  

The Impact of Isoniazid and Pyrazinamide Mono-resistance on Mortality among Tuberculosis Patients in Los Angeles County, 2010-2014 [PDF]

, 2017
Background: Isoniazid and pyrazinamide mono-resistant tuberculosis (TB) may be associated with poor treatment outcomes, but previous studies have found conflicting results.
Kaewalee Soontornmon
openalex   +3 more sources

Pyrazinamide Drug Resistance in Mycobacterium Tuberculosis: A Minireview

Journal of Bacteriology & Mycology: Open Access, 2016
Pyrazinamide (PZA) is a nicotinamide analog that is used as a frontline drug to treat tuberculosis (TB). It has special place in modern TB therapy, as it appears to kill a population of semi dormant tubercle bacilli persisting in the body. It is important drug because of its sterilizing activity against semi dormant tubercle bacilli. Although PZA has a
openaire   +1 more source

An explainable machine learning platform for pyrazinamide resistance prediction and genetic feature identification of Mycobacterium tuberculosis. [PDF]

J Am Med Inform Assoc, 2021
Zhang A, Teng L, Alterovitz G.
europepmc   +1 more source

Drug Exposure and Susceptibility of Pyrazinamide Correlate with Treatment Response in Pyrazinamide-Susceptible Patients with Multidrug-Resistant Tuberculosis

Pharmaceutics
Exploring the influence of pyrazinamide exposure and susceptibility on treatment response is crucial for optimizing the management of multidrug-resistant tuberculosis (MDR-TB). This study aimed to investigate the association between pyrazinamide exposure, susceptibility, and response to MDR-TB treatment, as well as find clinical thresholds for ...
Shulan Dong, Ge Shao, Lina Davies Forsman, Sainan Wang, Shanshan Wang, Jiayi Cao, Ziwei Bao, Judith Bruchfeld, Jan-Willem C. Alffenaar, Jia Liu, Yi Hu, Meiying Wu   +11 more
openaire   +3 more sources

Structural and Genomic Insights Into Pyrazinamide Resistance in <i>Mycobacterium tuberculosis</i> Underlie Differences Between Ancient and Modern Lineages. [PDF]

Front Mol Biosci, 2021
Tunstall T, Phelan J, Eccleston C, Clark TG, Furnham N.   +4 more
europepmc   +1 more source

The majority of patients with multidrug-resistant tuberculosis in Sub-Saharan Africa present a concomitant resistance to pyrazinamide

, 2016
Géraldine Daneau, Mourad Gumusboga, Pim de Rijk, Arnaud Trébucq, Leen Rigouts, Armand Van Deun, Bouke C. de Jong   +6 more
openalex   +1 more source

Missense Mutations in the Unfoldase ClpC1 of the Caseinolytic Protease Complex Are Associated with Pyrazinamide Resistance in Mycobacterium tuberculosis [PDF]

, 2016
Michelle Yee, Pooja Gopal, Thomas Dick
openalex   +1 more source

Mycobacterium tuberculosis pncA Polymorphisms That Do Not Confer Pyrazinamide Resistance at a Breakpoint Concentration of 100 Micrograms per Milliliter in MGIT [PDF]

, 2015
Michael G. Whitfield, Robin M. Warren, Elizabeth M. Streicher, Samantha L. Sampson, F A Sirgel, Paul D. van Helden, Alexandra Mercante, Melisa J. Willby, Kelsey Hughes, Kris Birkness, Glenn P. Morlock, Annelies Van Rie, James E. Posey   +12 more
openalex   +1 more source

Molecular investigation of mutation in PncA gene for pyrazinamide resistance in Mycobacterium tuberculosis: an in silico approach

, 2018
D. Ruban Durairaj, Shanmughavel Piramanayagam, M Whitfield, H Soeters, R Warren, T York, S Sampson, E Streicher, P Van Helden, A Van Rie, P Juren, J Werngren, J.-C Toro, S Hoffner   +13 more
openalex   +1 more source